New drug trial targets tough cancers that resist standard immunotherapy
NCT ID NCT04819373
Summary
This study tested an experimental immunotherapy drug called BDB001 for people with advanced solid tumors that had stopped responding to standard immune checkpoint inhibitor treatments. The trial aimed to see if BDB001 could help control cancer growth and was safe for patients. It was a Phase 2 study that included only one participant with various cancer types including lung, skin, kidney, and head and neck cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.